DPP4 and type 2 diabetes mellitus: In a clinical trial evaluating the effect of a combination of alogliptin (a DPP-4 inhibitor) and pioglitazone (a TZD) in treating drug-naïve patients with T2D, the combination treatment showed more significant reductions in HbA1c levels and fasting blood glucose levels than monotherapy alone.